Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 30, 2026

Progress on share buyback programme

View original at globenewswire.com
Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €1.0 billion share buyback programme announced on 30 April 2026, in total 860,000 shares were repurchased during the week of 22 June up to and including 26 June 2026…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ING Bank's more than 60,000 employees offer retail and wholesale banking services to customers in over 100 countries.

    60% confidence

  • ING's ESG rating by MSCI has been upgraded from 'AA' to 'AAA' in October 2025.

    60% confidence

  • In total 860,000 shares were repurchased during the week of 22 June up to and including 26 June 2026, at an average price of €27.65 for a total amount of €23,778,357.00.

    60% confidence

  • As of June 2025, in Sustainalytics' view, ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk).

    60% confidence

  • The total number of shares repurchased under this programme to date is 13,060,000 at an average price of €25.97 for a total consideration of €339,107,589.50, approximately 33.91% of the maximum total value of the share buyback programme.

    60% confidence

Data points we hold from this source

ING Group · average repurchase price weekly27.65 EUR
ING Group · buyback completion percent33.91 percent
ING Group · shares repurchased cumulative13060000 shares
ING Group · shares repurchased weekly860000 shares
ING Group · average repurchase price cumulative25.97 EUR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Progress on share buyback programme — Source | Via News | ViaNews EU